Kraepelin revisited: Schizophrenia from degeneration to failed regeneration

Molecular Psychiatry

Volumn 20, Issue 6, 2015, Pages 671-676

  Falkai, P ^a   Rossner, M J ^a,b   Schulze, T G ^a   Hasan, A ^a   Brzozka M M ^a   Malchow, B ^a   Honer, W G ^c   Schmitt, A ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; ENVIRONMENTAL STRESS; EPIGENETICS; HUMAN; MOLECULAR PATHOLOGY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPTOGENESIS; ANIMAL; ART; COGNITION DISORDERS; COMPLICATION; HISTORY; NERVE DEGENERATION; PHYSIOLOGY; REGENERATION;

ANIMALS; COGNITION DISORDERS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NERVE DEGENERATION; REGENERATION; SCHIZOPHRENIA;

EID: 84929944891     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.35     Document Type: Review

References (67)

1. Kraepelin E. Psychiatrie: Ein Lehrbuch für Studirende und Aertze [Psychiatry: A Textbook for Students and Doctors], 6th edn, JA Barth: Lepizig, Germany, 1899.
2. Alzheimer A. Neuere Arbeiten über die Dementia senilis [recent works on senile dementia]. Monatsschrift für Psychiatrie und Neurologie 1893; 3: 101-115.
3. Kraepelin E. Lehrbuch der Psychiatrie [Textbook of Psychiatry], 8th edn, JA Barth: Leipzig, Germany, 1913.
4. Bleuler E. Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken-und Familiengeschichten. Thieme: Stuttgart, Germany, 1908.
5. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97.
6. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Pschiatry Clin Neurosci 2000; 250: 274-285.
7. Häfner H, an der Heiden W. Course and outcome of schizophrenia. In: Hirsch R, Weinberger D (eds) Schizophrenia, 2nd edn, Blackwell: Malden, MA, USA, pp 101-139, 2003.
8. Marengo J. Classifying the courses of schizophrenia. Schizophr Bull 1994; 20: 519-536.
9. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogies Clin Neurosci 2010; 12: 393-407.
10. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res 2005; 78: 27-34.
11. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330.
12. Silverstein SM, Schenkel LS, Valone C, Nuernberger SW. Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia. Psychiatr Q 1998; 69: 169-191.
13. Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2010; 99: 245-253.
14. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-427.
15. Walters JT, Rujescu D, Franke B, Giegling I, Vásquez AA, Hargreaves A. The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am J Psychiatry 2013; 170: 877-885.
16. Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol Psychiatry 2014; 75: 276-283.
17. McAllister AK. Major histocompatibility complex I in brain development and schizophrenia. Biol Psychiatry 2014; 75: 262-268.
18. Pribiag H, Stellwagen D. Neuroimmune regulation of homeostatic synaptic plasticity. Neuropharmacology 2014; 78: 13-22.
19. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 2013; 39: 1129-1138.
20. Ellison-Wright I, Bullmore E. Anatomy of bipolardisorder and schizophrenia: a meta-analysis. Schizophr Res 2010; 117: 1-12.
21. De Peri L, Crescini A, Deste G, Fusar-Poli P, Sacchetti E, Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. Curr Pharm Des 2012; 18: 486-494.
22. Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009; 108: 3-10.
23. Hasan A, Wobrock T, Falkai P, Schneider-Axmann T, Guse B, Backens M et al. Hippocampal integrity and neurocognition in first-episode. schizophrenia: a multidimensional study. World J Biol Psychiatry 2014; 15: 188-199.
24. Kühn S, Gallinat J. Resting-state brain activity in schizophrenia and major depression: a quantitative meta-analysis. Schizophr Bull 2013; 39: 358-365.
25. Adriano F, Caltagirone C, Spalletta G. Hippocampal volume reduction in firstepisode and chornic schizophrenia: a review and meta-analysis. Neuroscientist 2012; 18: 180-200.
26. Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ. Systematic metareview and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012; 36: 1342-1356.
27. Bogerts B, Falkai P, Haupts M, Greve B, Ernst S, Tapernon-Franz U et al. Postmortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection. Schizophr Res 1990; 3: 295-301.
28. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985; 42: 784-791.
29. Wood SJ, Kennedy D, Phillips LJ, Seal ML, Yücel M, Nelson B. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 2010; 52: 62-68.
30. Schmitt A, Steyskal C, Bernstein HG, Schneider-Axmann T, Parlapani E, Schaeffer EL et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 2009; 117: 395-407.
31. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 1986; 236: 154-161.
32. Stocum DL. Regenerative Biology and Medicine. Academic Press: San Diego, CA, USA, 2010.
33. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch K-P. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-522.
34. Toro CT, Deakin JFW. Adult neurogenesis and schizophrenia: a window on abnormal early brain development. Schizophr Res 2007; 90: 1-14.
35. Schmitt A, Hasan A, Gruber O, Falkai P. Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 2011; 261: S150-S154.
36. Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol 2013; 23: 644-651.
37. Sawada K, Barr AM, Nakamura M, Arima K, Young CE, Dwork AJ. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry 2005; 62: 263-272.
38. Schmitt A, Leonardi-Essmann F, Durrenberger PF, Wichert SP, Spanagel R, Arzberger T et al. Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2012; 262: 565-577.
39. Anderson KK, Voineskos A, Mulsant BH, George TP, McKenzie KJ. The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanosms of neurotoxicity in first-episode psychosis. Can J Psychiatry 2014; 59: 513-517.
40. Pino O, Guilera G, Gómez-Benito J, Najas-Garcia A, Rufián S, Rojo E. Neurodevelopment of neurodegeneration: reviews of theories of schizophrenia. Actas Esp Psiquiatr 2014; 42: 185-195.
41. Brzózka MM, Radyushkin R, Wichert SP, Ehrenreich H, Rossner MJ. Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the forebrain. Biol Psychiatry 2010; 68: 33-40.
42. Brzózka MM, Rossner MJ. Deficits in trace fear memory in a mouse model of the schizophrenia risk gene TCF4. Behav Brain Res 2013; 237: 348-356.
43. Quednow BB, Brzozka MM, Rossner MJ. Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. Cell Mol Life Sci 2014; 71: 2815-2835.
44. Wirgenes KV, Sonderby IE, Haukvik UK, Mattingsdal M, Tesil M, Athanasiu L et al. TCF4 sequence variants and mRNA levels are associated with neurodevelopmental characteristics in psychotic disorders. Transl Psychiatry 2012; 2: E112.
45. Brennand KJ, Simone A, Jou J, Belboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
46. Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM et al. An in vivo correlated of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA 2007; 104: 5638-5643.
47. Erickson KI, Voss MW, Prakash RS, Basek C, Szabo A, Chaddock L et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 2011; 108: 3017-3022.
48. Biedermann S, Fuss J, Zheng L, Sartorius A, Falfan-Melgoza C, Demirakca T et al. In vivo voxel based morphometry: detection of increased hippocampal volume and decreased glutamate levels in exercising mice. Neuroimage 2012; 61: 1206-1212.
49. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 1999; 96: 13427-13431.
50. Naylor AS, Bull C, Nilsson MKL, Zhu C, Björk-Eriksson T, Eriksson PS et al. Voluntary running rescues adult hippocampal neurogenesis after irradiation of the young muse brain. Proc Natl Acad Sci USA 2008; 105: 14632-14637.
51. Morroni F, Kitazawa M, Drago D, Cheng D, Medeiros R, LaFerla FM. Repeated physical training and environmental enrichment induce neurogenesis and synaptogenesis following neuronal injury in an inducable mouse model. J Behav Brain Sci 2011; 1: 199-209.
52. Hasan A, Wobrock T, Rajji T, Malchow B, Daskalakis ZJ. Modulating neural plasticity with non-invasive brain stimulation in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013; 263: 621-631.
53. Frantseva MV, Fitzgerald PB, Chen R, Möller B, Daigle M, Daskalakis ZJ. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex 2008; 18: 990-996.
54. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry 2008; 65: 378-385.
55. Hasan A, Nitsche MA, Rein B, Schneider-Axmann T, Guse B, Gruber O et al. Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res 2011; 224: 15-22.
56. Fitzgerald PB, Brown TL, Marston NA, Oxley T, De Castella A, Daskalakis ZJ et al. Reduced plastic brain responses in schizophrenia: a transcranial magnetic stimulation study. Schizophr Res 2004; 71: 17-26.
57. Hasan A, Nitsche MA, Herrmann M, Schneider-Axmann T, Marshall L, Gruber O et al. Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. Brain Stimul 2012; 5: 475-483.
58. Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M et al. BDNFVal66Met-polymorphism imoact on cortical plasticity in schizophrenia patients: a proof-of-concept study. Int J Neuropsychopharmacol 2014; 18, e-pub ahead of print 31 October 2014; doi:10. 1093/ijnp/pyu040.
59. Pajonk FG, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010; 67: 133-143.
60. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. Front Neurosci 2014; 8: 19.
61. Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci 2013; 263: 273-284.
62. Wright C, Turner JA, Calhoun VD, Perrone-Bizzozero N. Potential impact of miR-137 and its targets in schizophrenia. Front Genet 2013; 4: 58.
63. Peter CJ, Akbarian S. Balancing histone methylation activities in psychiatric disorders. Trends Mol Med 2011; 17: 372-379.
64. Chase KA, Gavin DP, Guidotti A, Sharma RP. Histone methylation at H3K9: Evidence for a restrictive epigenome in schizophrenia. Schizophr Res 2013; 149: 15-20.
65. Kato T, Iwamoto K. Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders. Neuropharmacology 2014; 80: 133-139.
66. Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry 2014; 4: E339.
67. Fischer A, Sananbenesi F, Mungenast A, Tsai L-H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010; 31: 605-617.